Compare Hilton Hotels Corporation Common Stock (HLT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Neurocrine Biosciences Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.65 (market cap $73.63B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 4.2× Neurocrine Biosciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HLT | NBIX | |
|---|---|---|
Market Cap | $73.63B | $17.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $180.55 |
52-Week Low | $256.75 | $123.10 |
Enterprise Value | $86.12B | $16.49B |
Dividend Yield | 0.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
